IntraCellular Therapies (ITCI)
(Delayed Data from NSDQ)
$76.48 USD
+1.62 (2.16%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $76.46 -0.02 (-0.03%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Earnings News For ITCI
-
Why Is Intra-Cellular (ITCI) Up 1.2% Since Last Earnings Report?
-
Intra-Cellular (ITCI) Q1 Earnings and Sales Beat Estimates
-
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates
-
Intra-Cellular: Q1 Earnings Snapshot
-
Intra-Cellular Therapies Reports First Quarter 2024 Financial Results
-
Will Intra-Cellular Therapies (ITCI) Report Negative Q1 Earnings? What You Should Know
-
Intra-Cellular (ITCI) Q4 Loss Narrower Than Expected, Sales Miss
-
Intra-Cellular: Q4 Earnings Snapshot
-
Intra-Cellular Therapies Reports Fourth Quarter And Full-Year 2023 Financial Results And Provides Corporate Update
-
Intra-Cellular Therapies (ITCI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
-
Intra-Cellular (ITCI) Q3 Earnings Top, Product Sales View Raised
-
Intra-Cellular: Q3 Earnings Snapshot
-
Intra-Cellular Therapies Reports Third Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance
-
Intra-Cellular Therapies (ITCI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
-
Intra-Cellular (ITCI) Q2 Earnings & Sales Top, '23 View Raised
-
Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates
-
Intra-Cellular Therapies Reports Second Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance
-
Intra-Cellular (ITCI) Q1 Earnings Top, Caplyta Volume Rises
-
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates
-
Intra-Cellular: Q1 Earnings Snapshot
-
Intra-Cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update
-
Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Should You Buy?
-
Intra-Cellular (ITCI) Up 20.5% Since Last Earnings Report: Can It Continue?
-
Intra-Cellular (ITCI) Q4 Earnings & Sales Top, Caplyta Shines
-
Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates